Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Motsoako oa Pele oa Motsoako o Felletseng oa Motsoako oa Mofuta oa 2 oa Lefu la tsoekere

ngotsoeng ke mohlophisi

Glenmark Pharmaceuticals Limited e phatlalalitse motsoako o mocha oa tekanyetso e tsitsitseng (FDC) ea DPP4 inhibitor e sebelisoang haholo (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, le Pioglitazone. Ena ke eona feela mofuta oa motsoako oa DPP4 le Glitazone India bakeng sa batho ba baholo ba nang le lefu la tsoekere la Mofuta oa 2 le sa laoleheng. Glenmark e phatlalalitse FDC ena ka lebitso la Zita Plus Pio, e nang le Teneligliptin (20 mg) + Pioglitazone (15 mg), e nooang hang ka letsatsi.

Ha a bua ka tsoelo-pele, Alok Malik, Motlatsi oa Motlatsi oa Sehlopha & Hlooho, India Formulations - Glenmark Pharmaceuticals, o itse, "Lefu la tsoekere ke sebaka sa bohlokoa sa ho tsepamisa mohopolo ho Glenmark; pula-maliboho ea ho fana ka monyetla oa ho fumana mekhoa ea morao-rao ea phekolo ho bakuli ba nang le lefu la tsoekere India. Re thabetse ho hlahisa buka ena ea Zita Plus Pio, eo e leng ea pele ea mofuta oa eona India; e fana ka khetho ea boemo ba lefatše le ea theko e tlaase ho bakuli ba nang le lefu la tsoekere ba baholo. ”

Glenmark ke k'hamphani ea pele India ho bapatsa FDC ea boqapi ea Teneligliptin + Pioglitazone, e amohetsoeng ke DCGI (Kakaretso ea Molaoli oa Lithethefatsi oa India). Motsoako ona o sa fetoheng oa lethal dose o tla ba molemo ho bakuli ba hlokang kalafo ka Teneliglitptin le Pioglitazone (e le litlhare tse arohaneng) ho ntlafatsa taolo ea glycemic, ho fokotsa khanyetso ea insulin. 

Mofuta oa 2 oa lefu la tsoekere hangata o tobana le bothata ba ho se sebetse hantle ha lisele tsa β le ho hanyetsa insulin. Glenmark's FDC ea Teneligliptin + Pioglitazone e na le matla a ho sebetsana le mafu ana a mabeli a bohlokoa ka ho fetisisa a etsang hore FDC e atlehe ho laola lefu la tsoekere la Mofuta oa 2 le sa laoleheng. Motsoako oa Teneligliptin + Pioglitazone o tla fana ka mokhoa o ts'oanang moo Teneligliptin e tla ntlafatsa kutloisiso ea lisele tsa β, 'me Pioglitazone e fokotsa ho hanyetsa insulin ka nepo.

Tlatsetso ea Glenmark kalafong ea lefu la tsoekere

Ka selemo sa 2015, Glenmark e ile ea fetola 'maraka oa lefu la tsoekere ka ho tsebisa India inhibitor ea eona ea DPP4 - Teneligliptin, ea lateloa ke FDC ea Teneligliptin + Metformin. Glenmark e na le lefa le matla la lilemo tse fetang mashome a mane tsa tsoelopele le boqapi. Ha e ntse e tsoela pele ka lekhetlo la pele ho lefa India, e phatlalalitse FDC ea Teneligliptin + Remogliflozin ka 2021.

India e tsejoa e le motse-moholo oa lefu la tsoekere lefatšeng. Ho ea ka International Diabetes Federation (IDF), ho ata ha lefu la tsoekere India ho ka ba batho ba baholo ba limilione tse 74, e lebeletsoeng ho nyolohela ho limilione tse 125 (hoo e batlang e le keketseho ea 70%) ka 2045[i]. Ho bona, 77% ea bakuli ba na le lefu la tsoekere le sa laoleheng.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...